AULBIO

About AULBIO

AULBIO is a South Korean biotechnology company founded in 2018 that develops drug delivery technology to assist diabetic and obese patients. The company is focused on creating long-acting biopharmaceutical products that reduce dosing frequency through its proprietary platform, Extenna™ Microsphere Drug Delivery Technology. This system uses biodegradable and biocompatible polymer microspheres to encapsulate peptide drugs, allowing for sustained efficacy for one to six months from a single injection. The primary applications for this technology are in treatments for diabetes, obesity, and prostate cancer.

The company was founded in February 2018 and established its research institute in April of the same year. AULBIO's representative is Ted An, and its CTO is Cherngju Kim, PhD. Based in Seongnam, South Korea, the company has raised approximately $7.68M in funding through multiple rounds, including Series A and bridge financing from investors such as ES Investor, Enlight Ventures, Industrial Bank of Korea, and Kyung Dong Pharmaceutical Company. AULBIO has achieved several milestones, including being selected for the Korean government's TIPS Program in 2018 and the BIG3 Project in 2020. Its lead products in pre-clinical development include monthly injectable versions of Tirzepatide and Semaglutide.

AULBIO's business model revolves around the research, development, and eventual commercialization of its formulated brand products based on its drug delivery technology. The company's Extenna™ technology boasts a simple and reproducible aseptic manufacturing process, high encapsulation efficiency, and the ability to handle everything from small molecules to recombinant peptides. This aims to improve patient compliance and quality of life by significantly cutting down the number of required injections for chronic conditions.